Elkjær Lea Amalia Lind, Cédile Oriane, Hansen Marcus Høy, Nielsen Christian, Møller Michael Boe, Abildgaard Niels, Haaber Jacob, Nyvold Charlotte Guldborg
Haematology-Pathology Research Laboratory, Research Unit for Haematology and Research Unit for Pathology, University of Southern Denmark and Odense University Hospital, Odense, Denmark.
OPEN, Odense Patient data Explorative Network, Odense University Hospital, Odense, Denmark.
Leuk Res Rep. 2022 Aug 9;18:100341. doi: 10.1016/j.lrr.2022.100341. eCollection 2022.
High-dose chemotherapy followed by autologous stem cell transplantation (ASCT) has become a treatment option for fit patients with mantle cell lymphoma (MCL). However, these patients often relapse within few years, potentially caused by contaminating lymphoma cells within the reinfused stem cell product (SCP). Studies have shown that measurable residual disease, also termed minimal residual disease (MRD), following ASCT predicts shorter survival. Using next-generation sequencing, we explore whether the diagnostic MCL clonotype is present within the infused SCP. MRD was detected in 4/17 of the SCPs, ranging 4-568 clonal cells/100,000 cells. With a median survival of 17 months, 3/4 of patients with MRD+ graft succumbed from MCL relapse versus 2/13 in the MRD- fraction. Patients receiving MRD+ grafts had increased risk of mortality, and thus screening of SCPs may be important for clinical decision-making.
大剂量化疗后进行自体干细胞移植（ASCT）已成为适合的套细胞淋巴瘤（MCL）患者的一种治疗选择。然而，这些患者通常在几年内复发，这可能是由于回输的干细胞产品（SCP）中存在污染的淋巴瘤细胞所致。研究表明，ASCT后可测量的残留疾病，也称为微小残留疾病（MRD），预示着生存期较短。我们使用下一代测序技术，探究在输注的SCP中是否存在诊断时的MCL克隆型。在17份SCP中的4份检测到MRD，范围为4 - 568个克隆细胞/100,000个细胞。MRD阳性移植物的患者中，3/4因MCL复发死亡，而MRD阴性组为2/13。接受MRD阳性移植物的患者死亡风险增加，因此对SCP进行筛查可能对临床决策很重要。
